---
title: "BioStock: CLS presents study results and board changes"
date: "2025-02-10 23:16:42"
summary: "CLSDespite CLS’ decision to focus on commercialisation within neurosurgery, the company continues to present study results supporting the use of the TRANBERG system for the treatment of prostate cancer. Meanwhile, the company has announced a change in the board – Lars-Erik Eriksson, board member, former CEO, and co-founder, has decided..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

CLS

Despite CLS’ decision to focus on commercialisation within neurosurgery, the company continues to present study results supporting the use of the TRANBERG system for the treatment of prostate cancer. Meanwhile, the company has announced a change in the board – Lars-Erik Eriksson, board member, former CEO, and co-founder, has decided to step down from his position.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/cls-presents-study-results-and-board-changes/

This is a press release from**BioStock - Connecting Innovation & Capital**. https://www.biostock.se

https://news.cision.com/cls/r/biostock-cls-presents-study-results-and-board-changes%2Cc4103312

[Reuters](https://www.tradingview.com/news/reuters.com,2025-02-10:newsml_Wkr1H34n:0-biostock-cls-presents-study-results-and-board-changes/)
